Clinical evaluation of the response to treatment of PVRL. (A) Retinal photograph of a subretinal yellowish lesion corresponding to the lymphoma lesion before treatment (white arrow). (B) OCT image of the lesion described in panel A showing hyperreflective subretinal deposits (white star). (C) After systemic treatment, the subretinal lesion completely disappeared in the retinal photograph (yellow arrow). (D) In the OCT image, the subretinal deposits also disappeared (yellow asterisk). (E) In another patient, composite color fundus photograph (photographs merged together with built-in camera software) shows diffuse subretinal yellowish lesions corresponding to (sub)retinal infiltration by lymphoma cells captured before treatment (white arrow). In this patient, the vitreous was clear and free of visible lymphoma cells. The vitreous levels of IL-10 and IL-6 were low (36 and 6 pg/mL, respectively). A retinal biopsy was performed in the area of the asterisk to assess the diagnosis in this patient with pure retinal lymphoma. (F) Composite color fundus photograph (photographs merged together with built-in camera software) of patient shown in panel E after 2 courses of systemic chemotherapy (rituximab, HD MTX, procarbazine, and vincristine), showing the disappearance of most of the lesions (yellow arrow). The residual active lesions (blue arrows) disappeared after subsequent courses of chemotherapy. The scar from the retinal biopsy performed during diagnostic vitrectomy is visible on the nasal side of the optic nerve (yellow asterisk).